Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis
Zhousheng Xiao, … , Jeremy C. Smith, L. Darryl Quarles
Zhousheng Xiao, … , Jeremy C. Smith, L. Darryl Quarles
Published January 2, 2018; First published November 27, 2017
Citation Information: J Clin Invest. 2018;128(1):157-174. https://doi.org/10.1172/JCI93725.
View: Text | PDF
Categories: Research Article Bone biology Therapeutics

Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis

  • Text
  • PDF
Abstract

The molecular mechanisms that transduce the osteoblast response to physical forces in the bone microenvironment are poorly understood. Here, we used genetic and pharmacological experiments to determine whether the polycystins PC1 and PC2 (encoded by Pkd1 and Pkd2) and the transcriptional coactivator TAZ form a mechanosensing complex in osteoblasts. Compound-heterozygous mice lacking 1 copy of Pkd1 and Taz exhibited additive decrements in bone mass, impaired osteoblast-mediated bone formation, and enhanced bone marrow fat accumulation. Bone marrow stromal cells and osteoblasts derived from these mice showed impaired osteoblastogenesis and enhanced adipogenesis. Increased extracellular matrix stiffness and application of mechanical stretch to multipotent mesenchymal cells stimulated the nuclear translocation of the PC1 C-terminal tail/TAZ (PC1-CTT/TAZ) complex, leading to increased runt-related transcription factor 2–mediated (Runx2-mediated) osteogenic and decreased PPARγ-dependent adipogenic gene expression. Using structure-based virtual screening, we identified a compound predicted to bind to PC2 in the PC1:PC2 C-terminal tail region with helix:helix interaction. This molecule stimulated polycystin- and TAZ-dependent osteoblastogenesis and inhibited adipogenesis. Thus, we show that polycystins and TAZ integrate at the molecular level to reciprocally regulate osteoblast and adipocyte differentiation, indicating that the polycystins/TAZ complex may be a potential therapeutic target to increase bone mass.

Authors

Zhousheng Xiao, Jerome Baudry, Li Cao, Jinsong Huang, Hao Chen, Charles R. Yates, Wei Li, Brittany Dong, Christopher M. Waters, Jeremy C. Smith, L. Darryl Quarles

×

Figure 1

Effects of combined Pkd1 and Taz deficiency on bone mass in 8-week-old mice.

Options: View larger image (or click on image) Download as PowerPoint
Effects of combined Pkd1 and Taz deficiency on bone mass in 8-week-old m...
(A) BMD in femurs by dual-energy x-ray absorptiometry scan. (B) Micro-CT analysis of distal femoral metaphysis and midshaft diaphysis. (C) Periosteal mineral apposition rate (MAR) by calcein double labeling. (D) OsO4 staining of decalcified tibiae by micro-CT analysis. (E) TRAP staining (red color) for osteoclast activity. Data are presented as the mean ± SD from 6–8 individual mice (n = 6–8). P values were determined by 1-way ANOVA with Newman-Keuls multiple-comparisons test. *Significant difference from WT control mice, #significant difference from Taz+/– mice, &significant difference from Pkd1+/– mice at P < 0.05, respectively. BV/TV, bone volume density; Ct.Th, cortical thickness; Ad.V/Ma.V, adipocyte volume per marrow volume; Ad.N, adipocyte number; Oc.S/BS, osteoclast surface per bone surface.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts